New York, USA - March 22, 2023 - Alzheimer's disease is a type of neurodegenerative disorder. "Drugs to treat this disorder are always moving forward, and Creative Biolabs is actively contributing to the research of drug discovery and development for central nervous system (CNS) disorders," stated an experienced representative at Creative Biolabs.
The expert went on to introduce that Creative Biolabs, boasting a team of experienced scientists and best-in-class technologies, is dedicated to optimizing and improving the drug discovery and development process.
CNS Drug Discovery
Creative Biolabs has developed a comprehensive STEMOD™, an advanced drug discovery platform that covers every critical stage of CNS drug discovery. This platform is equipped with advanced technologies, including neuroscience in vitro models, neuroscience assay technologies, and neuroscience research tools, making it a one-stop shop for researchers worldwide.
Additionally, Creative Biolabs supports specialized drug discovery services for various neurological diseases such as neurodegenerative disorders, neuromuscular disorders, brain tumors, and psychiatric disorders.
"Developing new drugs from initial idea to final products is a complex and time-consuming process that involves in vitro and in vivo preclinical studies. Creative Biolabs offers assistance in drug development from preclinical to clinical."
• Peptide Array Technology Service
The peptide array widely used in proteomics research is employed for drug development and molecular interactions. For challenging screening of large numbers of peptides, Creative Biolabs offers an innovative and flexible solution, NeuSPOT™ peptide array technology, which synthesizes and screens up to 10,000 peptides or peptide mixtures on the surface of cellulose or other membranes. The NeuSPOT™ technology can also be applied to cell-based bioassays, neural connectivity and cell adhesion, regenerative medicine, etc.
• Therapeutic Nanoplatform for Neurological Disorders
The representative further explained, "Obtaining clinical approval for most newly developed drugs is a challenging task due to limited access to the blood-brain barrier (BBB). However, the turnaround came with the nanotechnology that has provided a breakthrough to overcome this obstacle."
Creative Biolabs launches a nanotechnology platform that offers a bespoke nanoparticle (NP) service based on diverse nanoparticles, including liposomes, dendrimers, viral capsids, polymeric nanoparticles, silicon nanoparticles, and magnetic/metallic nanoparticles. These NP-based drug carriers enable the effective delivery of drugs across the BBB.
More details about technical services related to drugs for neurological disorders can be fetched at https://www.creative-biolabs.com.
The experienced scientists at Creative Biolabs are aided by advanced platforms and innovative in-house techniques to explore new approaches for the pharmaceutical industry, significantly advancing our clients' research projects in the field of neurology. Creative Biolabs has the expertise to optimize each stage of the process to ensure that you achieve the desired results with maximum efficiency.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Country: United States